Short supply of Provenge constrains Dendreon's sales; Sanofi advances dengue vaccine;

 @FierceBiotech: Biogen restructuring claims 650 jobs. Article | Follow @FierceBiotech

> Dendreon announced $79.3 million in losses for the third quarter, despite its prostate cancer drug Provenge's growing sales. The company expects revenue to pick up in 2011, with half of its forecasted $350 to $400 million coming in the fourth quarter of that year. Article

> Sanofi Pasteur's dengue vaccine has entered its first Phase III clinical study in Australia. The study is part of a global Phase III clinical study program aimed at advancing the development of a novel vaccine for the prevention of dengue disease in children and adults. Report

> A study published in the New England Journal of Medicine showed that Novartis' drug Afintor reduced the size of subependymal giant cell astrocytomas, which are brain tumors associated with 20 percent of tuberous sclerosis patients. Novartis release

> German drug company 4SC AG announced positive preliminary Phase IIa results for its interleukin-17 inhibitor vidofludimus as an inflammatory bowel disease treatment. The drug enhanced patients' response rates to 88.5 percent, compared to the placebo's 20 percent over a 12 week treatment window. 4SC release

> Derek Lowe of In The Pipeline looks at pharmas, biotechs and universities and breaks down the numbers on where drugs come from. Post

 And Finally... Higher income parents are increasingly forgoing kids' vaccinations. Article

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.